
Chronic glucocorticoid exposure, even at low doses, is now seen by regulators and clinicians as an unacceptable safety burden. Sponsors that prioritize steroid-toxicity from the outset position ...
“When patients can track their own experience of steroid‑toxicity and take that data straight into the clinic, they stop being passive recipients and start driving the conversation.” Clinicians know ...
New data presented at EULAR 2025 show Sam’s rapid user growth and increasing importance to patients. At the American College of Rheumatology (ACR) Annual Meeting in Washington, DC, Steritas released ...
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
Academic institutions worldwide are increasingly adopting the clinical outcome assessments (COA) of steroid-toxicity that make up the STOX® Suite from Steritas. To date, 26 academic licenses are in ...